REGENXBIO Secures $100M Milestone from AbbVie as Diabetic Retinopathy Trial Advances

summarizeSummary

REGENXBIO received a $100 million milestone payment from AbbVie for advancing its diabetic retinopathy gene therapy into a Phase IIb/III trial, significantly boosting its financial position.

check_boxKey Events · Product Development and Regulatory · RGNX

• $100 Million Milestone Payment Received

  REGENXBIO announced it has earned a $100 million milestone payment from AbbVie, expected to be received in July 2026.

• Diabetic Retinopathy Trial Advances to Phase IIb/III

  The milestone was triggered by the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial of surabgene lomparvovec (sura-vec) in diabetic retinopathy using suprachoroidal delivery.

• Significant Boost to Financial Runway

  This substantial cash infusion, representing nearly 18.5% of the company's market capitalization, provides critical financial stability, especially following recent "going concern doubts" disclosed in the last 10-Q.

• Upcoming Clinical Data Presentations

  The company plans to present two and a half-year data from the ALTITUDE trial (sura-vec for DR) and five-year follow-up data from the Phase I/IIa study (sura-vec for wet AMD) at the ASRS 2026 Annual Meeting in July.

auto_awesomeAnalysis · RGNX · Life Sciences

REGENXBIO has received a substantial $100 million milestone payment from AbbVie, triggered by the first patient dosed in the Phase IIb/III trial for surabgene lomparvovec in diabetic retinopathy. This significant cash infusion, representing nearly 18.5% of the company's market capitalization, provides critical financial runway and addresses previous "going concern doubts" highlighted in the recent 10-Q. The advancement of this late-stage clinical program also validates the company's gene therapy pipeline and its collaboration with AbbVie.